Identification of a Novel Prognostic Classification Model in Epithelial Ovarian Cancer by Cluster Analysis

通过聚类分析识别上皮性卵巢癌的新型预后分类模型

阅读:4

Abstract

BACKGROUND: Heterogeneity plays an essential role in ovarian cancer. Patients with different clinical features may manifest diverse patterns in diagnosis, treatment, and prognosis. The aim of the present study was to identify a novel ovarian cancer-classification model through cluster analysis and assess its significance in prognosis. METHODS: Among patients diagnosed with ovarian cancer in the Women's Hospital School of Medicine, Zhejiang University between January 2014 and May 2019, 328 patients were included in a K-mean cluster analysis and 176 patients followed up. Major clinical indicators, overall survival, and recurrence-free survival in different subgroups were compared. RESULTS: Two clusters for ovarian cancer were identified and grouped as noninflammatory (n=247) and inflammatory subtypes (n=81). Compared with the noninflammatory subgroup, the inflammatory subgroup presented a statistically significantly higher level of median CRP (median (IQR) 20.4 [7.8-47.3] vs 1.2 [0.4-3.5], p<0.001), neutrophil percentage (median (IQR) 76.9 [72.6-81.3] vs 66.2 [61.0-72.0], p<0.001), leukocyte count (median (IQR) 8.9 [7.0-10.0] vs 6.0 [5.1-7.2], p<0.001), fibrinogen (median (IQR) 5.0 [4.4-6.0] vs 3.4 [2.9-3.9], p<0.001), and platelet count (median (IQR) 324 [270-405] vs 229 [181.5-269], p<0.001). During a median follow-up of 52 months, 21 participants (16.3%) died in the noninflammatory group, while 14 (29.8%) died in the inflammatory group (HR 2.15, 95% CI 1.09-4.23; p=0.024). Death/recurrence was observed in 38 (29.5%) patients from the noninflammatory group and 25 (53.2%) from the inflammatory group (HR 2.32, 95% CI 1.40-3.85; p<0.001). CONCLUSION: Our study revealed a novel classification model of ovarian cancer that features inflammation. Inflammation predicts shorter survival and poorer prognosis, suggesting the significance of inflammation in the management of ovarian cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。